A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients with Advanced Solid Tumors
B
Bert O'Neil, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The purpose of this study is to determine the highest doses of BBI608 and BBI503 that can be safely given to patients when the drugs are given together.
Description
The purpose of this study is to determine the highest doses of BBI608 and BBI503 that can be safely given to patients when the drugs are given together.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Solid Tumor
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
18 Apr 2024.
Study ID: 1503065100 (BBI401-101)
